This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Raymond, E. Articles by Armand, J.-P. Search for Related Content PubMed PubMed Citation Articles by Raymond, E. Articles by Armand, J.-P. Social Bookmarking                            What's this?

Dosage Adjustment and Pharmacokinetic Profile of Irinotecan in Cancer Patients With Hepatic Dysfunction

From the Department of Medicine, Gustave Roussy Institute, Villejuif, and Aventis Pharma, Vitry-sur-Seine, France.

Address reprints requests to Eric Raymond, MD, PhD, Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France; email: raymond{at}igr.fr

PURPOSE: To determine the recommended dose (RD) and the pharmacokinetic profile of irinotecan and its metabolites in cancer patients with hyperbilirubinemia.

PATIENTS AND METHODS: Patients were assigned to four treatment groups according to their baseline total bilirubin level. Patients in group I (bilirubin within normal range) and group II (bilirubin 1.0 to 1.5 times upper limit of normal [ULN]) received a dose of 350 mg/m² every 3 weeks. Patients in groups III (bilirubin 1.51 to 3.0 times ULN) and IV (bilirubin > 3.1 times ULN) received starting doses of 175 and 100 mg/m², respectively. RDs were defined according to the dose-limiting toxicity (DLT) experienced at cycle 1.

RESULTS: Thirty-three patients including 21 gastrointestinal cancers were included. Grade 4 febrile neutropenia and diarrhea were common DLTs in patients with hyperbilirubinemia. At a dose of irinotecan 350 mg/m², DLTs were observed in two of seven and one of five patients in groups I and II, respectively. In group III, escalated doses of irinotecan 175, 200, and 240 mg/m² were associated with DLTs in one of seven, one of five, and three of six patients, respectively. No DLT was observed in group IV. High bilirubin and alkaline phosphatase levels were associated with an exponential decrease in the clearance of irinotecan. Pharmacokinetic analysis showed that the relative increase in exposure was likely caused by reduced biliary excretion.

CONCLUSION: We showed that baseline total bilirubin level could be used to determine the appropriate dose of irinotecan in cancer patients with hepatic dysfunction. Doses of 350 mg/m² and 200 mg/m² were considered RDs in patients with bilirubin values 1.5 times ULN and 1.51 to 3.0 times ULN, respectively.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. K. Ramanathan, M. J. Egorin, C. H.M. Takimoto, S. C. Remick, J. H. Doroshow, P. A. LoRusso, D. L. Mulkerin, J. L. Grem, A. Hamilton, A. J. Murgo, et al. Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group J. Clin. Oncol., February 1, 2008; 26(4): 563 - 569. [Abstract] [Full Text] [PDF]

				D. Superfin, A. A. Iannucci, and A. M. Davies Commentary: Oncologic Drugs in Patients with Organ Dysfunction: A Summary Oncologist, September 1, 2007; 12(9): 1070 - 1083. [Abstract] [Full Text] [PDF]

				M. Michael, M. Thompson, R. J. Hicks, P. L. Mitchell, A. Ellis, A. D. Milner, J. Di Iulio, A. M. Scott, V. Gurtler, J. M. Hoskins, et al. Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination J. Clin. Oncol., September 10, 2006; 24(26): 4228 - 4235. [Abstract] [Full Text] [PDF]

				L. J. Schaaf, L. A. Hammond, S. J. Tipping, R. M. Goldberg, R. Goel, J. G. Kuhn, L. L. Miller, L. D. Compton, L. A. Cisar, G. L. Elfring, et al. Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction. Clin. Cancer Res., June 15, 2006; 12(12): 3782 - 3791. [Abstract] [Full Text] [PDF]

				S. Kim, C. N. Prichard, M. N. Younes, Y. D. Yazici, S. A. Jasser, B. N. Bekele, and J. N. Myers Cetuximab and Irinotecan Interact Synergistically to Inhibit the Growth of Orthotopic Anaplastic Thyroid Carcinoma Xenografts in Nude Mice Clin. Cancer Res., January 15, 2006; 12(2): 600 - 607. [Abstract] [Full Text] [PDF]

				A. Rogatko, J. S. Babb, M. Tighiouart, F. R. Khuri, and G. Hudes New Paradigm in Dose-Finding Trials: Patient-Specific Dosing and Beyond Phase I Clin. Cancer Res., August 1, 2005; 11(15): 5342 - 5346. [Abstract] [Full Text] [PDF]

				F. A. de Jong, S. Marsh, R. H. J. Mathijssen, C. King, J. Verweij, A. Sparreboom, and H. L. McLeod ABCG2 Pharmacogenetics: Ethnic Differences in Allele Frequency and Assessment of Influence on Irinotecan Disposition Clin. Cancer Res., September 1, 2004; 10(17): 5889 - 5894. [Abstract] [Full Text] [PDF]

				J. A. Meyerhardt, A. Kwok, M. J. Ratain, J. P. McGovren, and C. S. Fuchs Relationship of Baseline Serum Bilirubin to Efficacy and Toxicity of Single-Agent Irinotecan in Patients With Metastatic Colorectal Cancer J. Clin. Oncol., April 15, 2004; 22(8): 1439 - 1446. [Abstract] [Full Text] [PDF]

				A. P. Venook, C. Enders Klein, G. Fleming, D. Hollis, C. G. Leichman, R. Hohl, J. Byrd, D. Budman, M. Villalona, J. Marshall, et al. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863 Ann. Onc., December 1, 2003; 14(12): 1783 - 1790. [Abstract] [Full Text] [PDF]

				M. G. Schlieman, H. S. Ho, and R. J. Bold Utility of Tumor Markers in Determining Resectability of Pancreatic Cancer Arch Surg, September 1, 2003; 138(9): 951 - 956. [Abstract] [Full Text] [PDF]

				R. H. J. Mathijssen, S. Marsh, M. O. Karlsson, R. Xie, S. D. Baker, J. Verweij, A. Sparreboom, and H. L. McLeod Irinotecan Pathway Genotype Analysis to Predict Pharmacokinetics Clin. Cancer Res., August 1, 2003; 9(9): 3246 - 3253. [Abstract] [Full Text] [PDF]